Paul Fabela, MD
Internal Medicine · Fort Worth, TXNPI 1700103132
Payments from drug & device makers
Across 224 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$805
- Lilly USA, LLC$530
- Boehringer Ingelheim$295
- AstraZeneca$233
- Abbott$221
- GSK$193
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,943100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $805 |
| Lilly USA, LLC | 33 | $530 |
| Boehringer Ingelheim | 17 | $295 |
| AstraZeneca | 11 | $233 |
| Abbott | 10 | $221 |
| GSK | 10 | $193 |
| Sanofi-aventis U.S. LLC | 10 | $180 |
| AbbVie | 9 | $145 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $122 |
| Dexcom, Inc. | 6 | $112 |
| Astellas Pharma US Inc | 6 | $104 |
| Cipher Pharmaceuticals US LLC | 1 | $84 |
| Merck | 6 | $83 |
| Corcept Therapeutics | 2 | $69 |
| Eisai Inc. | 3 | $63 |
| Johnson & Johnson | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $34 |
| Si-bone, Inc. | 2 | $34 |
| Bayer | 2 | $32 |
| Antares Pharma, Inc. | 2 | $26 |
| Pfizer | 1 | $22 |
| Bausch Health US, LLC | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Amgen | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Optinose US, Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 2 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$3,943 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 161 | $206,550 |
| EliquisApixaban | 127 | $137,779 |
| JardianceEmpagliflozin | 76 | $88,523 |
| TrulicityDulaglutide | 33 | $52,552 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $51,335 |
| MounjaroTirzepatide | 38 | $45,873 |
| JanuviaSitagliptin Phosphate | 18 | $26,414 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $21,124 |
| LinzessLinaclotide | 19 | $18,402 |
| XareltoRivaroxaban | 24 | $17,372 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $16,999 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $15,981 |
| MyrbetriqMirabegron | 16 | $13,637 |
| TradjentaLinagliptin | 16 | $12,589 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 421 | $10,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir | $805 | $208,700173 claims |
| PfizerEliquis, Paxlovid | $22 | $140,638148 claims |
| Boehringer IngelheimJardiance, Tradjenta | $295 | $101,11292 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $530 | $98,42571 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $193 | $67,31681 claims |
| MerckJanuvia, Janumet | $83 | $47,53839 claims |
| AbbVieLinzess, Synthroid | $145 | $21,21662 claims |
| Johnson & JohnsonXarelto | $58 | $17,37224 claims |
| Astellas Pharma US IncMyrbetriq | $104 | $13,63716 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $180 | $9,95317 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $122 | $5,51414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Fort Worth
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.